[go: up one dir, main page]

WO1993008260A1 - Levures contenant des cytochromes multiples de mammifere pour degrader des melanges chimiques complexes - Google Patents

Levures contenant des cytochromes multiples de mammifere pour degrader des melanges chimiques complexes Download PDF

Info

Publication number
WO1993008260A1
WO1993008260A1 PCT/US1992/009033 US9209033W WO9308260A1 WO 1993008260 A1 WO1993008260 A1 WO 1993008260A1 US 9209033 W US9209033 W US 9209033W WO 9308260 A1 WO9308260 A1 WO 9308260A1
Authority
WO
WIPO (PCT)
Prior art keywords
enzymes
cytochrome
yeast
population
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1992/009033
Other languages
English (en)
Inventor
Henry W. Strobel
Terry B. White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO1993008260A1 publication Critical patent/WO1993008260A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
    • A62D3/00—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances
    • A62D3/02—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by biological methods, i.e. processes using enzymes or microorganisms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09C—RECLAMATION OF CONTAMINATED SOIL
    • B09C1/00—Reclamation of contaminated soil
    • B09C1/10—Reclamation of contaminated soil microbiologically, biologically or by using enzymes
    • C—CHEMISTRY; METALLURGY
    • C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
    • C10G—CRACKING HYDROCARBON OILS; PRODUCTION OF LIQUID HYDROCARBON MIXTURES, e.g. BY DESTRUCTIVE HYDROGENATION, OLIGOMERISATION, POLYMERISATION; RECOVERY OF HYDROCARBON OILS FROM OIL-SHALE, OIL-SAND, OR GASES; REFINING MIXTURES MAINLY CONSISTING OF HYDROCARBONS; REFORMING OF NAPHTHA; MINERAL WAXES
    • C10G32/00—Refining of hydrocarbon oils by electric or magnetic means, by irradiation, or by using microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
    • A62D2101/00—Harmful chemical substances made harmless, or less harmful, by effecting chemical change
    • A62D2101/20—Organic substances

Definitions

  • the present invention relates to the functional expression of multiple, eukaryotic cytochrome P450s in yeast cells and populations of yeast, genetic constructs for affecting such expression and methods employing these yeast cells or populations of yeasts and/or the recombinant enzymes produced by such cells or populations of cells for metabolizing chemically-complex cytochrome P450 substrates, particularly complex chemical mixtures.
  • the invention relates, in an important respect, to the use of such recombinant yeast cells and populations of such cells to affect metabolism of crude oils and related products.
  • the invention relates to the ability of the recombinant yeasts or populations of yeasts, to express functional, multiple, eukaryotic cytochrome P450s cloned therein and to degrade various constituents of petroleum.
  • cytochrome P450 proteins (generally referred to as ,l P450s") . These proteins utilize electrons from reduced nucleotide phosphates (NADPH or NADH) to activate molecular oxygen.
  • NADPH or NADH reduced nucleotide phosphates
  • the reducing equivalents are relayed to the cytochrome P450 via one or two additional but distinct proteins (e.g., redu ⁇ tases) that together form a short electron-transport chain.
  • cytochrome P450 The general reaction catalyzed by cytochrome P450 is as follows:
  • RH is a suitable P450 substrate and ROH is its hydroxylated product.
  • the microsomal system which catalyzes this reaction is composed of a cytochrome P450 reductase and a family of cytochrome P450 isozymes associated with microsomal membranes of the cell.
  • cytochrome P450 The substrates of cytochrome P450 are lipophilic molecules frequently containing multiple ring structures. Some major functions of cytochrome P450 proteins include the metabolism of drugs and other foreign compounds, steroidogenesis and bile acid production from cholesterol, and ⁇ -oxidation of fatty acids and prostaglandins (for reviews on cytochrome P450, see, White and Coon, 1980; Adesnik and Atchison, 1986; Nebert and Gonzalez, 1987; and Black and Coon, 1986) .
  • cytochrome P450 proteins are diverse and it is, therefore, helpful to categorize them.
  • the first major dichotomy is between eukaryotic and prokaryotic P450s.
  • the bacterial P450s form a large class of soluble proteins, in contrast to the eukaryotic enzymes, which are all integral membrane proteins.
  • P450s many vertebrate sequences are known.
  • enzymes from rats have been purified and characterized (Dignam and Strobel, 1977) as have various other P450 isozymes (Saito and Strobel, 1981; Lau and Strobel, 1982) .
  • the enzymes are found in two cellular locations, the mitochondria and the endoplasmic reticulum.
  • the mitochondrial enzymes catalyze the earliest steps in the conversion of cholesterol into steroid hormones.
  • the endoplas ic-reticulum enzymes are referred to as microsomal P450s.
  • the microsomal P450s can be divided into two groups on the basis of their substrates.
  • the microsomal P450s act on endogenous substrates. They are involved in steroid- hormone biosynthesis and metabolism and in the metabolism of fatty acids and prostaglandins and may be referred to as endogenous P450s.
  • the majority of sequenced microsomal P450s act on compounds foreign to the host cell such as drugs and petroleum products. They constitute part of a detoxification system and may be referred to as the xenobiotic-metabolizing P450s.
  • cytochrome P450s capable of drug and xenobiotic metabolism.
  • These proteins can be induced up to 70-fold by the administration of drugs or xenobiotics.
  • the proteins fall into two families that are induced by two different classes of drugs, the phenobarbital (PB) family and the 3-methylcholanthrene (MC) family.
  • Figure 1 lists the cytochrome P450 sequences grouped into protein families (nomenclature of Dayhoff, 1979) .
  • the wide capability of mammalian cytochromes to degrade complex chemical mixtures matches the composition of crude oil and petrochemical wastes.
  • Cytochrome P450 genes are arranged in multigene families that together constitute a gene super family. The actual number of P450 genes in mammals is not known, but a lower limit may be estimated on the basis of molecular- hybridization studies. Two non-cross reacting probes have indicated a minimum of 15 genes in the PB family (Atchison and Adesnik 1983; Mizukami et al. 1983). Five rat and six rabbit P450 sequences are known, so approximately one-third of the genes in these species have been sequenced.
  • the MC family also has a number of genes. Two sequences each are known in rats, mice, and humans. Three are present in rabbits.
  • the glucocorticoid-inducible P450 PCN also called P450 p ) shows six to eight hybridization bands (Gonzalez et al. 1985) .
  • P450 C21 is present as two genes in each of cattle, mice, and humans, with only one gene each functional in mice and man (Chung et al. 1986a) .
  • the LA ⁇ family contains two or three genes (Hardwick et al. 1987) .
  • P450 17 ⁇ There are at least six additional P450 proteins in mammals: P450 17 ⁇ , P450 scc , P450 11/3, P450 aro atase, 25- hydroxy vitamin D 3 l ⁇ -hydroxylase, and cholesterol 26 hydroxylase. Therefore, the minimum number of P450 genes is 33, with the possibility that there are others (for a more complete discussion of the genetics of cytochrome P450, see Adesnik and Atchison 1986) .
  • Eukaryotic P450s have been cloned and expressed in bacterial expression systems. For instance, Porter et al. (1987) relates to the expression of a functional mammalian cytochrome P450 reductase in E. coli. Japanese Patent 2,016,976 relates to recombinant cytochrome "bS" reductase expression in E. coli. Unfortunately, however, the present understanding in the art is that many eukaryotic cytochrome P450s cannot be expressed functionally in bacteria (Cullin, et al., 1988) .
  • Eukaryotic cytochrome P450s have been expressed in eukaryotic expression systems, as well.
  • yeasts containing the activity for aromatic hydrocarbon degradation may be used in seeding experiments for clean-up of toxic wastes in the environment.
  • Other related yeast proteins have also been recombinantly expressed in yeast.
  • Japanese Patent 2,000,451 relates to the cloning of a yeast cytochrome P450 reductase in E. coli.
  • Yeasts are known to be capable of heterologous expression of eukaryotic P450s from other eukaryotes, as well.
  • Japanese Patent Applications 63,044,888 and 62,104,583 both relate to chimeric mammalian (rat liver) genes expressed in yeast which produce protein fusions between cytochrome P450IA1 (also called "P450MC” from yeasts) and a reductase or P450IA1 and P450d, respectively.
  • the latter fusion protein results from part of IA1 (i.e. HR2 region of P450MC) being substituted with part of P450d ("the same region of P450d”) .
  • Japanese Patent 1,047,380 relates to a yeast strain that produces bovine cytochrome P450 XVIIA1 from a recombinant plasmid. This particular cytochrome reacts with progesterone or pregnenolone.
  • Japanese Patent Application (62,019,085) relates to the expression of rat liver cytochrome P450 reductase in Saccharomyces cerevisiae. This cytochrome is expressed from a recombinant plasmid using an alcohol dehydrogenase promoter.
  • U.S. Patent 4,766,068 issued to Hiroko et al. relates to the expression of rat liver cytochrome P450 IA1 ("P450MC”) in Saccharomyces cerevisiae from a recombinant plasmid using the yeast alcohol dehydrogenase promoter.
  • Means are needed for: (1) simply and rapidly inducing stable cytochromes capable of initiating the degradation of the complex mixtures found in a given petroleum mixture by oxidizing varied groups of compounds which are the substrates of different cytochrome P450s; (2) expressing the combinations of cytochromes suitable for the given petroleum product; (3) expressing such combinations of cytochromes in situ in an environment free of intense selection for the genetic construction encoding the selected cytochromes; (4) achieving this expression in an organism capable of safe, intentional environmental release; and (5) potentially improving the degradative capabilities of the naturally-occurring cytochromes.
  • the present invention seeks to overcome one or more problems and deficiencies in the prior art by providing populations of recombinant yeast cells that encode at least two distinct P450 enzymes thereby assisting in the biodegradation of complex mixtures of chemical compounds such as hydrocarbon mixtures, e.g., petroleum product mixtures.
  • hydrocarbon mixtures e.g., petroleum product mixtures.
  • the present invention relates to the creation of a number of yeast strains and/or populations of such yeast cells, which are optimized in their degradation of alkane, asphaltene, aromatic, etc., compounds.
  • yeasts are eukaryotes, they possess an endoplasmic reticulum and as such represent a better host for functioning of the mammalian cytochrome P450s than do the prokaryotes of the prior art approaches.
  • yeast or other simple eukaryote expression systems for expressing biologically active eukaryotic cytochrome P450s which incorporate the advantages of yeast cell expression.
  • novel technology as is disclosed herein which addresses one or more of these disadvantages would have broad research and commercial applications including drug development and environmental clean up.
  • the present invention relies on the fact that yeast, as opposed to other commonly used eukaryotic cellular systems, have the ability to survive in a variety of environmental situations.
  • yeast as opposed to other commonly used eukaryotic cellular systems, have the ability to survive in a variety of environmental situations.
  • the substrate specificity of mammalian P450 enzymes will improve the native oil- degradative ability of the yeast strains substantially.
  • the potential of the engineered yeast for use in detoxification of wastes in the environment would have many advantages over systems currently used.
  • yeast strains which contain at least pairs of stable P450 isozymes with different specific activities for the different substrates found in crude oil. Furthermore, a method is disclosed in the present invention for eliminating a particular petroleum waste from a given site by analyzing the crude mixture to determine the relative amounts of alkanes, asphaltenes, and aromatic compounds present, and then to introduce the strains of yeast which can best degrade those components.
  • the present invention overcomes at least some of the disadvantages of the prior art.
  • no requirement is made for man-made chimeric enzymes. This is especially advantageous since environmental release of such organisms away from intense selection techniques found in cultured conditions seriously undermine the usefulness of chimeric proteins.
  • the present invention takes advantage of the ability of single isozymes of P450 to attack a number of slightly different compounds. This is in part due to the ability of such cytochrome P450s to bind a variety of substrates while including selected combinations of such enzymes to complement the complex mixture of compounds in a petroleum product. Since yeast represent a host which potentially may be distributed outside the laboratory environment, a more flexible approach to environmental degradation of complex chemical mixtures is possible.
  • the advantages of the invention over the prior art are achieved by providing: (1) a simple and rapid means for inducing stable, naturally-occurring cytochromes capable of initiating the degradation of the complex mixtures found in a given petroleum mixture by inducing such enzymes in eukaryotes and cloning the genes therefor; (2) a means for coordinately expressing the combinations of cytochromes suitable for the given petroleum product; (3) a means for expressing such combinations of cytochromes in situ in an environment free of intense selection for the genetic construction encoding the selected cytochromes; (4) achieving this expression in an organism or population of organisms capable of safe, intentional environmental release; and (4) potentially improving the degradative capabilities of the naturally- occurring cytochromes.
  • FIG. 1 Construction of Yeast Vectors Containing
  • Figure 3 CO Difference Spectra Comparing Yeast Vectors With and Without Mammalian Cytochrome P450b.
  • the invention provides a population of stably transformed yeast cells recombinantly expressing at least a first and a second biologically active eukaryotic cytochrome P450 enzyme.
  • the yeast cell population may be an homogenous population in which each yeast cell constituting the population is a virtually identical sister cell of a single parental cell containing the same genetic information as the parent cell.
  • the genetic material contained within each sister cell in the population will encode the necessary genes to express at least two of the recombinant eukaryotic cytochrome P450s.
  • the population may, on the other hand, represent a heterologous population of yeast cells.
  • a single cell line may contain all of the genetic information necessary to express at least two recombinant eukaryotic cytochrome P450s
  • the invention provides for a mixed population in which single recombinant eukaryotic P450s may be encoded by different cells within the population.
  • the enzymes expressed within the population are chosen for their capacity to degrade at least two distinct chemical components of an admixture such as petroleum mixtures.
  • the enzymes recombinantly established in the populations of the invention may be selected to degrade any of the general classes of compounds which are typically found in such complex hydrocarbon mixtures such as short chain alkanes, long chain alkanes, cyclic alkanes, substituted alkanes, simple aromatic hydrocarbons, complex aromatic hydrocarbons, substituted aromatic hydrocarbons or the like.
  • the recombinant enzymes may be encoded in more than one plasmid or other genetic vector. In many instances, however, it will likely be preferred to clone both recombinant enzymes into a single plasmid which is then transformed into a single progenitor cell. Where there is a single plasmid encoding both of the recombinant cytochrome P450s, the enzymes may be operatively linked each to a separate promoter sequence.
  • the genes encoding the separate enzymes will be operatively linked to a single promoter sequence.
  • Such gene hook-ups may resemble a coordinately controlled operonic system where a first gene is downstream of a second gene and each is controlled by a promoter sequence immediately upstream of the first gene.
  • a hook-up where a bi ⁇ directional promoter is operatively linked on either of its flanking regions to one or the other of the two recombinant P450s.
  • a bi-directional promoter is provided by the invention by example as the GAL1-GAL10 promoter sequence.
  • Other promoters that may be substituted include the alcohol dehydrogenase promoter of yeast.
  • the population of yeast cells of the invention is constructed to possess first and second eukaryotic enzymes for the degradation of selected first and second substrates. This is most readily achieved by selecting each enzyme from any of the different known cytochrome P450 families possessing eukaryotic P450 members. These families are represented in Figure 1. Thus, for example, the first enzyme may be chosen from the cytochrome P450 I, II, III, IV, VI, XIA, XIB, XVII, XIX, XXI or XXVI family. Similarly, the second enzyme is chosen from the same or a different one of these families.
  • the selection of the individual enzyme or the family of enzymes from which it is to be chosen is dictated by the constituents of the complex chemical admixture which is to be attacked.
  • the invention is particularly concerned with the design of such populations capable of degrading admixtures comprising petrochemical components, select components of which are degradable by a eukaryotic cytochrome P450 enzyme.
  • the invention further provides a process for constructing a population of stably transformed yeast cells recombinantly expressing at least two distinct biologically active eukaryotic cytochrome P450 enzymes capable of degrading different chemical components of an admixture. This process is initiated by inducing expression of at least two cytochrome P450 enzymes by administering at least two different components of the complex chemical admixture to eukaryotic subject animals, typically rats or other laboratory animals, in order to induce transcription of mRNA encoding the cytochrome P450 produced by the animal to metabolize the administered compound.
  • test animals are then sacrificed and the mRNA is collected from their tissues (typically liver) and cDNA corresponding to the mRNA is isolated.
  • sequence information is available (preferably DNA sequence information although amino acid sequence information will suffice)
  • the cDNA gene sequences encoding the cytochrome P450s are then isolated by hybridization to short oligonucleotide probes by techniques known well to those of skill in the art.
  • the isolated cDNA sequences are then cloned in yeast expression vectors and inserted into yeast cells.
  • the invention also provides a stably transformed yeast cell which expresses at least two independent biologically active eukaryotic cytochrome P450 enzymes.
  • active enzymes are encoded in recombinant cytochrome P450 genes and are operatively associated with those necessary expression elements which are capable of effecting yeast transcription and translation of said genes such as yeast-compatible ribosome binding sites, spacer regions, transcription terminators, and promoters capable of promoting expression of the genes.
  • the genetic constructions of the invention may be placed on any number of vehicles known well to those of skill in the art so long as such vehicle allows the cloned gene to be expressed in a yeast cell.
  • plasmids such as pMAC561, pBINK may be useful in this regard.
  • yeast cells may, in addition to the cytochrome P450 enzymes, possess other recombinant enzymes.
  • an enzyme normally associated with the electron transfer apparatus of the membrane bound eukaryotic P450s such as a eukaryotic cytochrome P450 reductase.
  • the invention further provides a method for the simultaneous production of at least two biologically active eukaryotic cytochrome P450 enzymes.
  • the method comprises preparing the yeast cell population in accordance with the previously discussed techniques and then growing the cell population under conditions appropriate to effectuate expression of the cytochrome P450 enzymes.
  • the conditions under which the yeast cell population is grown will be under highly controlled, laboratory or bioreactor conditions. Under these conditions, the chief goal will be to maximize production of the enzyme without undue concern for permanently establishing the population in the laboratory environment.
  • yeast populations may also be established, in some cases relatively permanently, in the natural environment or at least in environments where other eukaryotic cell lines would not prosper.
  • the methods of the invention provide for initiating the growing of the yeast cell population by releasing the yeast cell population into an open environment or natural environment such as a pond, lake, field, tilled soil, or other situs in which the introduction of such population is desired. It is suggested that such environments might be of particular interest where the environment has been contaminated by a petrochemical.
  • a method for the metabolism of eukaryotic cytochrome P450 substrates comprises preparing a yeast cell population which expresses at least two biologically active recombinant cytochrome P450 enzymes in accordance with previously discussed techniques. Again, the expressed enzymes are selected for their capability to metabolize selected substrates of interest. Then, the method calls for subjecting the substrates to the enzymes so produced under conditions conducive to metabolizing the substrates. This may be achieved with the whole cells of such yeast populations. Alternatively, it may be achieved where the enzymes are at least partially purified from said yeast cell population prior to subjecting the substrates to the enzymes. In some cases it may be preferable to at least partially maintain the integrity of the cell membranes with which the cytochrome P450s and reductases are associated.
  • a DNA segment is also provided in the invention which comprises at least two gene sequences encoding at least two biologically active eukaryotic cytochrome P450 enzymes capable of degrading distinct chemical components of an complex admixture.
  • This DNA segment may further comprise cytochrome P450 enzyme genes modified to allow yeast expression of the encoded cytochrome P450 enzymes in a biologically active form. This is typically achieved by incorporating yeast-compatible ribosome binding sites, spacer regions, transcription terminators, and promoters capable of effecting yeast expression of said genes.
  • a variety of alkanes may be used to treat rats. Observations of the induction of messenger RNA for isozymes specific for the different alkanes will then be carried out.
  • yeast expressing P450 isozymes IA1 and IA2 may be used for crude mixtures containing high levels of polyaromatic compounds.
  • yeast expressing P450 isozymes IIC11 and IIE1 for crude mixtures containing high levels of alkanes, use of a combination of yeast strains expressing P450 isozymes IIC11 and IIE1, as well as the other forms listed in Figure 1 with their specificities for crude oil components is advisable.
  • plasmid pRS315 it may be best to use a combination of different yeast strains in varying proportions.
  • use of the cloned rat NADPH P450 reductase expressed in plasmid pRS315 will be advisable in certain instances.
  • Both plasmids may be carried in the same yeast strain YPH 499, or another similar GAL+ strain, such as GRF167 altered to contain the trpl and leu2 mutations.
  • Crude oil mixtures will be analyzed by the company or field which owns the oil.
  • the composition will vary but the classes of compounds usually are reflected in broad solubility classes.
  • pentane extraction is used to separate out all soluble compounds from the tarry asphaltenes.
  • the pentane extract is further extracted by hexane, benzene or other solvents, into fractions. These gross fractions will typically be characterized further with a variety of analytical techniques (e.g. gas chromatography, high performance liquid chromatography, mas spectrometry) .
  • the contents fall into general categories, alkanes and simple and complex aromatic compounds.
  • the yeast strain 20B-12 Jones 1977 containing a PEP4 mutation Jones 1977 was transformed with a plasmid pBINK, which contains the P450IIB1 cDNA gene oriented 5' to 3' in functional linkage with the yeast alcohol dehydrogenase promoter; or with a plasmid pKNIB, with the gene in the opposite orientation functionally linked to the same promoter ( Figure 2) .
  • the plasmids were transformed into yeast by the lithium acetate transforation procedure such as that described in Current Protocols in Molecular Biology, Vol. 2 (Wiley Interscience, 1989) .
  • a reduced CO difference spectrum which spectrum is capable of detecting the presence of the cytochrome P450, was performed on the yeasts using 2 x 10 9 cells/ml in 0.1M potassium phosphate buffer, pH 7.5. These spectra were achieved by methods known well to those of skill in the art.
  • the cDNA gene for P450IIB1 was expressed in these yeast cells from the alcohol dehydrogenase promoter. This was demonstrated by an increase in absorbance at 454 nm in a CO difference spectrum (Fig. 3) . The expression was no different when the yeast were grown with or without oxygen. No cytochrome P450 was detected in cells containing the vector alone.
  • the transformed yeast strains were tested for their ability to grow on oil-containing plates. This was accomplished by the procedures of Walker and Colwell (1976) . All of the strains grew poorly or not at all on plates containing crude oil as the major carbon source (results not shown) . This lack of growth occurred whether or not minor carbon sources such as minimal concentrations of glycerol were initially present in the medium.
  • cytochrome P450IA1 (P450c) was expressed from a GAL promoter in the plasmid pOLVl.
  • This plasmid was constructed using the GAL1-GAL10 promoter from the plasmid pBM150 (Johnston and Davis, 1984) inserted into the yeast- E. coli shuttle vector pRS316 (Sikorski and Hieter, 1989) .
  • the BamHI-EcoRI fragment of pBM150 containing the GAL1-GAL10 promoter was cloned into the BamHI-EcoRI site of the multiple cloning site of the vector pRS316 to form pOLVI.
  • IA1 Several clones of IA1 were obtained by amplification using the polymerase chain reaction technique (PCR) .
  • the IA1 isozyme was previously cloned by Hines et al. (1985) .
  • Hines et al. (1985) Using the DNA sequence data published by these researchers, the present researchers designed oligonucleotides and then used these oligonucleotides in the amplification of cDNA from / 3-naphthoflavone-treated rat liver.
  • the amplified DNA was subjected to electrophoresis and was removed from the gel.
  • the fragment thus amplified and purified was then cloned into pBLUESCRIPT KS(+) (Stratagene) by blunt end ligation, and confirmed by restriction analysis.
  • pBLUESCRIPT KS(+) Stratagene
  • P450IA1-PCR clones Cl, C33, C35, and C47 all showed some cross-reactivity to the antibody.
  • Determination of the sequence of the P450IA1 clones obtained by PCR amplification was carried out.
  • the BaroHI- Hindlll restriction fragments from pBLUESCRIPT containing P450IA1-PCR were cloned into bacteriophage M13 for sequencing for three of the clones. Approximately 300 base pairs were sequenced from either the N-terminus or the C- terminus of the resulting protein, depending on orientation of the clone in the original pBLUESCRIPT.
  • P450IA1 cloned by PCR amplification of rat hepatic RNA demonstrated certain mutations from the sequences known in the prior art. In certain cases, such mutations will not cause deleterious changes in the resulting protein. However, it will be understood by those of skill in the art that standard DNA sequencing of the resulting DNA may be achieved to verify that a DNA fragment contains an accurate sequence for a given cytochrome. This may be further confirmed by assaying for the respective activity as noted above.
  • yeast strain YPH499 containing the IA1- PCR clones Cl, C33, C35, or C47 was grown in minimal medium with galactose as the sole carbon source. The cells were harvested in stationary phase and a reduced CO difference spectrum was obtained from each strain (as described above) . No significant difference was found in the amount of absorbance in the 450-460 nm range. However, there was a difference in peak position for one of the clones indicating the desired activity was present in this clone. Cells expressing the cloned cytochrome were shown to remain viable but not to grow on media containing crude petroleum.
  • strains of yeast containing these plasmids for those with improved metabolism of petroleum and petroleum products. This may be accomplished by introducing random mutations into the transformed cells and selecting mutants with increased growth on petroleum.
  • Rat P450 reductase may be incorporated into the yeast strains of the invention on a separate plasmid, pRS315 (Sikorski and Hieter, 1989) . Incorporation of rat reductase along with the other clones of the invention may be advisable since its presence in the cell would potentially improve the function of the expressed rat P450s. Such inclusion is, however, not a requirement for the successful use of the yeast strains of the invention.
  • Cytochrome P450IA1 the enzymatic activities of which enzyme have been shown to be induced in rat liver and kidney following feeding of the rats with Prudhoe Bay crude oil (Khan and Rahimtula, 1987) , was used for studies herein.
  • a genomic clone encoding P450IA1 (Hines, et al., 1985) was used to probe a cDNA library from rat liver (Clontech Laboratories) for a complete cDNA clone of P450IA1 by standard techniques (Maniatis et al., 1982) as shown above.
  • the cDNA clone was placed in the yeast shuttle vector YEp24 (Botstein et al., 1979).
  • YEp24 is able to replicate under antibiotic selection in E. coli by virtue of its pBR322 sequences, and can replicate under uracil selection in yeast due to the 2 micron episomal DNA sequences and the presence of the yeast URA3 gene.
  • the heterologous P450 gene was expressed from the URA3 promoter.
  • This vector has the advantage of a high copy number so that expression of plasmid-borne genes will occur at a higher level than that of a chromosomal gene using the same promoter.
  • URA3 promoter is less stringently regulated and will permit transcription under a variety of growth conditions.
  • YEp24 has previously been used successfully to express another type of cytochrome P450 (lanosterol demethylase) in yeast (Kalb, et al. , 1986) .
  • cytochrome P450IA1 was confirmed by Western analysis of crude extracts of yeast by the method of Loper et al. (1985) . As shown above, antibodies to rat cytochrome P450IA1 were used to identify the enzyme's presence in yeast. Expression of the mammalian cytochrome P450 was measured by an elevation in benzo(a)pyrene hydroxylase activity over the same yeast strain which did not contain the -heterologous enzyme.
  • Yeast strains carrying the genetic constructions of the invention will be altered to enhance the likelihood that they will not survive in the environment without oil.
  • rho minus yeast which yeasts are unable to carry out respiration for energy
  • rho minus yeast which yeasts are unable to carry out respiration for energy
  • glucose metabolism steps may be used.
  • each strain to be disabled will have to be selectively so disabled depending on the (relatively) specific degradation task to which the strain will be put.
  • the mutagenesis of the selected strains while growing on crude oil plates will be accomplished. This will be followed by replica-plating to glucose or glycerol- containing plates and detection of colonies unable to grow. By so selecting those that are unable to grow, ability of the strains to grow on certain readily found carbon sources in the environment will be diminished.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Environmental & Geological Engineering (AREA)
  • Soil Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Emergency Management (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne l'expression fonctionnelle du cytochrome eucaryotique multiple P450 dans des cellules de levures, des produits de recombinaison génétique pour réaliser une telle expression, et des méthodes utilisant ces cellules de levures et/ou les enzymes recombinantes ainsi produites pour métaboliser des substrats chimiquement complexes du cytochrome P450. L'invention concerne, dans un aspect important, l'utilisation de telles cellules de levures recombinantes pour agir sur le métabolisme des pétroles bruts. En particulier, l'invention concerne la capacité des levures transformées génétiquement à dégrader différents constituants du pétrole brut, grâce au cytochrome eucaryotique multiple P450 apporté par le clonage.
PCT/US1992/009033 1991-10-22 1992-10-22 Levures contenant des cytochromes multiples de mammifere pour degrader des melanges chimiques complexes Ceased WO1993008260A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78109791A 1991-10-22 1991-10-22
US781,097 1991-10-22

Publications (1)

Publication Number Publication Date
WO1993008260A1 true WO1993008260A1 (fr) 1993-04-29

Family

ID=25121691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/009033 Ceased WO1993008260A1 (fr) 1991-10-22 1992-10-22 Levures contenant des cytochromes multiples de mammifere pour degrader des melanges chimiques complexes

Country Status (2)

Country Link
AU (1) AU2896092A (fr)
WO (1) WO1993008260A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0644267A3 (fr) * 1993-07-20 1996-07-24 Sumitomo Chemical Co Méthode pour l'évaluation d'innocuite d'un composé chimique utilisant la levure récombinante exprimant la cytochrome P450 humaine.
WO2001068907A3 (fr) * 2000-03-14 2002-04-25 Johannes Doehmer Expression stable de formes polymorphes de cytochromes humains p450 2d6 en tant qu'outil analytique dans la mise au point preclinique de medicaments

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0132309A2 (fr) * 1983-06-27 1985-01-30 The Board Of Trustees Of The Leland Stanford Junior University Elément promoteur eucaryotique réglable
EP0360361A1 (fr) * 1988-09-23 1990-03-28 Roussel-Uclaf Procédé pour l'oxydation multiple des stéroides et cellules génétiquement modifiées pour cet usage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0132309A2 (fr) * 1983-06-27 1985-01-30 The Board Of Trustees Of The Leland Stanford Junior University Elément promoteur eucaryotique réglable
EP0360361A1 (fr) * 1988-09-23 1990-03-28 Roussel-Uclaf Procédé pour l'oxydation multiple des stéroides et cellules génétiquement modifiées pour cet usage

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, Volume 65, issued 1987, S. KHAN et al., "Effect of a Prudhoe Bay Crude Oil on Hepatic and Placental Drug Metabolism in Rats", pages 2400-2408. *
JOURNAL OF BIOCHEMISTRY, Volume 101, No. 5, issued 1987, Y. IMAI, "Cytochrome P-450 Related to P-450(4) from Phenobarbital-Treated Rabbit Liver: Molecular Cloning of cDNA and Characterization of Cytochrome P-450 Obtained by its Expression in Yeast Cells", pages 1129-1139. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0644267A3 (fr) * 1993-07-20 1996-07-24 Sumitomo Chemical Co Méthode pour l'évaluation d'innocuite d'un composé chimique utilisant la levure récombinante exprimant la cytochrome P450 humaine.
US6620593B1 (en) 1993-07-20 2003-09-16 Sumitomo Chemical Company, Limited Method for safety evaluation of chemical compound using recombinant yeast expressing human cytochrome P450
WO2001068907A3 (fr) * 2000-03-14 2002-04-25 Johannes Doehmer Expression stable de formes polymorphes de cytochromes humains p450 2d6 en tant qu'outil analytique dans la mise au point preclinique de medicaments

Also Published As

Publication number Publication date
AU2896092A (en) 1993-05-21

Similar Documents

Publication Publication Date Title
Pompon et al. [6] Yeast expression of animal and plant P450s in optimized redox environments
Urban et al. Maximizing the expression of mammalian cytochrome P-450 monooxygenase activities in yeast cells
Ost et al. Rational re-design of the substrate binding site of flavocytochrome P450 BM3
Hayano et al. Protein disulfide isomerase mutant lacking its isomerase activity accelerates protein folding in the cell
JP3283551B2 (ja) 酵母中でスクアレンおよび特異的なステロールの蓄積を増加させるための方法と組成物
Gachotte et al. Characterization of the Saccharomyces cerevisiae ERG26 gene encoding the C-3 sterol dehydrogenase (C-4 decarboxylase) involved in sterol biosynthesis
Cauet et al. Pregnenolone esterification in Saccharomyces cerevisiae: A potential detoxification mechanism
Drăgan et al. Efficient conversion of 11-deoxycortisol to cortisol (hydrocortisone) by recombinant fission yeast Schizosaccharomyces pombe
Yim et al. Surface display of heme-and diflavin-containing cytochrome P450 BM3 in Escherichia coli: a whole cell biocatalyst for oxidation
Wiersma et al. Squalene-tetrahymanol cyclase expression enables sterol-independent growth of Saccharomyces cerevisiae
Reifschneider-Wegner et al. Expression of the [FeFe] hydrogenase in the chloroplast of Chlamydomonas reinhardtii
Nthangeni et al. The use of Yarrowia lipolytica for the expression of human cytochrome P450 CYP1A1
Yang et al. Cytochrome P450 for environmental remediation: catalytic mechanism, engineering strategies and future prospects
CN102382805A (zh) 具有氧化还原酶活性的多肽及其用途
Roy et al. Cloning and characterization of the gene encoding lipoamide dehydrogenase in Saccharomyces cerevisiae
Permana et al. Latent functions and applications of cytochrome P450 monooxygenases from Thamnidium elegans: a novel biocatalyst for 14α-hydroxylation of testosterone
CN113528606B (zh) 一种酶催化制备17β-羟基类固醇的方法
US5635369A (en) Yeast strains with stable integration of heterologous genes
Darnet et al. Functional identification of sterol‐4α‐methyl oxidase cDNAs from Arabidopsis thaliana by complementation of a yeast erg25 mutant lacking sterol‐4α‐methyl oxidation1
CN117106737B (zh) 一种维生素d3的c25位羟化酶突变体及其基因工程菌与应用
DE69729097T2 (de) Cytochrom p450 expression in enterobakterien
ZIMMER et al. In vivo reconstitution of highly active Candida maltosa cytochrome P450 monooxygenase systems in inducible membranes of Saccharomyces cerevisiae
AU635494B2 (en) Process for the biochemical oxidation of steroids and genetically engineered cells to be used therefor
CN118909983A (zh) 一种p450bm3突变体在甾体药物合成中的应用
EP0876495A1 (fr) Souches de levures genetiquement modifiees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA